Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on December 11, 2024, by Haleon Plc (LSE/NYSE: HLN), discloses transactions by Persons Discharging Managerial Responsibilities (PDMRs) in accordance with the UK Market Abuse Regulation. Haleon is a global consumer health leader with brands including Advil, Sensodyne, and Panadol.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding disclosures.
Material Changes and Transactions
On December 10, 2024, two PDMRs executed transactions on the London Stock Exchange (XLON) under the Company's Share Reward Plan:
- Adrian Morris (General Counsel): Acquired 33 Partnership Shares at £3.7313 per share and received 33 Matching Shares at no cost. Total aggregated volume: 66 shares.
- Tamara Rogers (Chief Marketing Officer): Acquired 33 Partnership Shares at £3.7313 per share and received 33 Matching Shares at no cost. Total aggregated volume: 66 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory notification of specific share transactions.
Investor Verification Checklist
- Verify the total number of shares held by Adrian Morris and Tamara Rogers post-transaction against previous filings.
- Confirm the terms of the Share Reward Plan regarding the matching share mechanism.
- Review the current market price of Haleon ordinary shares (GB00BMX86B70) relative to the transaction price of £3.7313.